- Home
- NBN vs ETNB Comparison
NBN vs ETNB Comparison
Compare NBN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- ETNB
- Stock Information
- Founded
- NBN 1872
- ETNB 2018
- Country
- NBN United States
- ETNB United States
- Employees
- NBN N/A
- ETNB N/A
- Industry
- NBN Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- NBN Finance
- ETNB Health Care
- Exchange
- NBN Nasdaq
- ETNB Nasdaq
- Market Cap
- NBN 753.2M
- ETNB 867.4M
- IPO Year
- NBN N/A
- ETNB 2019
- Fundamental
- Price
- NBN $91.78
- ETNB $7.94
- Analyst Decision
- NBN Buy
- ETNB Buy
- Analyst Count
- NBN 2
- ETNB 7
- Target Price
- NBN $91.00
- ETNB $30.33
- AVG Volume (30 Days)
- NBN 66.2K
- ETNB 1.3M
- Earning Date
- NBN 01-28-2025
- ETNB 11-07-2024
- Dividend Yield
- NBN 0.04%
- ETNB N/A
- EPS Growth
- NBN 12.22
- ETNB N/A
- EPS
- NBN 7.69
- ETNB N/A
- Revenue
- NBN $157,668,000.00
- ETNB N/A
- Revenue This Year
- NBN N/A
- ETNB N/A
- Revenue Next Year
- NBN $10.37
- ETNB N/A
- P/E Ratio
- NBN $11.93
- ETNB N/A
- Revenue Growth
- NBN 16.87
- ETNB N/A
- 52 Week Low
- NBN $49.07
- ETNB $6.43
- 52 Week High
- NBN $105.44
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- NBN 37.01
- ETNB 47.27
- Support Level
- NBN $96.78
- ETNB $6.43
- Resistance Level
- NBN $99.50
- ETNB $8.09
- Average True Range (ATR)
- NBN 2.97
- ETNB 0.60
- MACD
- NBN -1.35
- ETNB -0.07
- Stochastic Oscillator
- NBN 7.13
- ETNB 48.24
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).